Application of Advanced CRISPR/Cas-9 and Other Genomic Tools in RNA-Based Therapeutics

Опубликована: Янв. 1, 2025

Язык: Английский

---

Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine

Frontiers in Microbiology, Год журнала: 2025, Номер 16

Опубликована: Апрель 28, 2025

Foot-and-mouth disease virus (FMDV) is one of the most significant animal pathogens worldwide, severely impacting health and productivity pigs, cattle, sheep, other ungulates. Although traditional vaccines have played a crucial role in epidemic control, inactivated face persistent challenges concerning potential for dissemination pressures from serotype subtype matching. However, manufacture attenuated forbidden, efficiency alternative immune protection still inadequate. Consequently, there exists an urgent need safer more effective innovative husbandry. In this study, we aimed to develop lipid nanoparticle mRNA vaccine based on VP1-3A-3D epitopes O FMD verify its specific expression within cytoplasmic injection sites. Our findings demonstrated that transfected into primary spleen cells derived guinea pigs induced cytokine release, promoted differentiation both CD4+ T CD8+ lymphocytes, enhanced lymphocyte proliferation rates. Following immunization observed increased cells, alongside elevated levels secretion. Additionally, vaccination production IgG antibodies as well neutralizing antibodies. Importantly, our provided complete all six against lethal challenge 100 GPID50, with histopathological scores indicating equivalent conferred by vaccine. The viral load results group significantly reduced copy numbers serum effectively decreased concentration inflammatory IL-1β. Furthermore, during pre-immune phase following heightened secretion was observed, along inhibition replication. Simultaneously, antibody titer remained stable over 4 months. Immunofluorescence analysis tissues marked activation macrophages, group. summary, study suggests promising candidate further development fight FMDV.

Язык: Английский

---

Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle

Vaccines, Год журнала: 2025, Номер 13(5), С. 473 - 473

Опубликована: Апрель 28, 2025

With the successful deployment of several mRNA vaccines against SARS-CoV-2, an vaccine RSV (respiratory syncytial virus) and a large pipeline products other infectious diseases, cancers rare it is important to examine whole product lifecycle. technology enables design, testing manufacturing systems be rapidly developed, but these advantages can lost if factors that determine public access are not closely considered. This review analyzes key aspects lifecycle including candidate manufacturing, quality safety storage. Regulatory thinking well advanced in some countries others, more thought on regulation outside pandemic situation as therapeutics individual neoantigen therapies disease treatments needed. Consumer acceptance-the "social license operate" around products-is critical for their uptake, particularly pandemic.

Язык: Английский

---

mRNA Vaccines

Опубликована: Янв. 1, 2025

---

Unlock the sustained therapeutic efficacy of mRNA

Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113837 - 113837

Опубликована: Май 1, 2025

Язык: Английский

---